+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 55Years +
All Genders
ID06659445

Evaluating ONL1204 and Other Eye Injections for Geographic Atrophy in Age-Related Macular Degeneration A Randomized, Controlled Phase 2 Study

Led by ONL Therapeutics · Updated on 2026-09-10

324

Participants Needed

120

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the safety and effectiveness of a drug called ONL1204 in people aged 55 and older who have geographic atrophy GA related to age-related macular degeneration AMD. GA associated with AMD is a leading cause of vision loss and blindness globally, linked to aging and other risk factors. This phase 2 study aims to understand how different doses and treatment schedules of ONL1204 affect this condition. Participants will receive one of several treatments ONL1204 injections at two dose levels 100 or 200 micrograms every 12 weeks, ONL1204 200 micrograms every 24 weeks, sham injections every 12 or 24 weeks, or monthly injections of avacincaptad pegol. All injections are given into the eye intravitreal. This randomized, double-masked trial compares these different groups over a period of 48 weeks. During the study, participants will have regular visits for eye exams, imaging, and vision tests to monitor their condition and treatment effects. Researchers will track safety and efficacy outcomes throughout the 48 weeks. Participants must meet specific vision and eye health criteria to join, and safety monitoring will continue throughout the treatment period to ensure participant well-being.

CONDITIONS

Brief Title

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

Research Team

S

Study Coordinator

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here